Detect and Profile Multiple Myeloma Measurable Residual Disease (MRD )Prognostics for Monitoring Post-transplant Multiple Myeloma (MM) Patients Receiving Maintenance Therapy.
Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY
The purpose : Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Confirmed MM diagnosis
• Transplant eligible patients in a first remission
• Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed)
• Availability of deidentified patient's demographic and clinical follow up data
• Receiving standard of care treatment
• Able to provide informed consent
Locations
Other Locations
Canada
Jewish General Hospital
RECRUITING
Montreal
Contact Information
Primary
Rayan Kaedbey, MD FRCPC
rayan.kaedbey.med@ssss.gouv.qc.ca
514-340-8222
Time Frame
Start Date: 2024-05-01
Estimated Completion Date: 2028-09
Participants
Target number of participants: 70
Treatments
MRD level group
Participants will be defined as diagnosed with multiple myeloma
Related Therapeutic Areas
Sponsors
Leads: Sir Mortimer B. Davis - Jewish General Hospital